The Significance of Increased Soluble Cytotoxic T-Lymphocyte Associated Antigen 4 in systemic Lupus Erythematosus
【摘要】：Objective: To investigate the expression of sCTLA4 in SLE patients, comparing sCTLA4 concentrations between active and inactive SLE patients with normal controls, and determine whether there is correlation between sCTLA4 and the clinical status of SLE patients.
1. Blood from SLE patients that came to outpatients or was admitted at dermatology and venereology department of Chongqing First Affiliated Hospital from February 2009 to July 2009 were included in the study. A total 40 SLE patients were collected, 15 patients in active stage and 8 patients in inactive stage of SLE.
2. As a comparison blood from medical check up people from February 2009 to July 2009 were included. 17 persons were used as healthy control in this study.
1. Determine the disease activity from each SLE samples using SLEDAI score
2. Quantitative sCTLA4: 200μl serum of each sample was extracted and using ELISA kit (Bender medsystems, GmbH, Vienna, Austria) detecting the quantity of sCTLA4.
3. Expression of sCTLA4 mRNA: mRNA was extracted from PBMCs and the quantity was detected using real time PCR
4. Results were analyzed with SPSS 13 statistical software by using a student T-test, one way ANOVA and linear regression. Finding was considered statistically significant if the P value 0.05.
Results: A total of 23 samples with SLE and 17 healthy controls were collected through February 2009 to July 2009 from dermatology and venereology department of Chongqing First Affiliated Hospital. All of the SLE samples are female. Our results showed that sCTLA4 expression both in active and inactive SLE patients are significantly higher than the healthy controls. But there were no correlation between sCTLA4 values with SLE disease activity.
Conclusions: This study showed that even though the expression of sCTLA4 was higher in SLE patients compared to healthy controls, the increasing sCTLA4 have no relationship with the activity of SLE disease. Thus sCTLA4 role as biomarker for SLE is still in question.